Baader Bank Aktiengesellschaft Buys 2,274 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Baader Bank Aktiengesellschaft increased its holdings in Gilead Sciences by 21.0% in Q1, purchasing an additional 2,274 shares, bringing its total ownership to 13,118 shares valued at approximately $1.45 million.
• Several hedge funds have significantly increased their stakes in Gilead, with FMR LLC raising its stake by 21.6% and GAMMA Investing LLC increasing its stake by a staggering 13,891.1% in the last quarter.
• Analysts are optimistic about Gilead, with Needham & Company upgrading the stock to a "buy" rating and multiple firms adjusting their price targets upward, indicating a overall consensus rating of "Moderate Buy."

Baader Bank Aktiengesellschaft lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,118 shares of the biopharmaceutical company's stock after acquiring an additional 2,274 shares during the quarter. Baader Bank Aktiengesellschaft's holdings in Gilead Sciences were worth $1,453,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mesirow Financial Investment Management Inc. lifted its holdings in Gilead Sciences by 6.3% during the 1st quarter. Mesirow Financial Investment Management Inc. now owns 7,434 shares of the biopharmaceutical company's stock worth $833,000 after purchasing an additional 442 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in Gilead Sciences by 94.6% during the 1st quarter. Arkadios Wealth Advisors now owns 45,750 shares of the biopharmaceutical company's stock worth $5,126,000 after purchasing an additional 22,240 shares in the last quarter. Brucke Financial Inc. purchased a new stake in Gilead Sciences during the 1st quarter worth about $244,000. XTX Topco Ltd lifted its holdings in Gilead Sciences by 76.8% during the 1st quarter. XTX Topco Ltd now owns 9,156 shares of the biopharmaceutical company's stock worth $1,026,000 after purchasing an additional 3,976 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd lifted its holdings in Gilead Sciences by 20.2% during the 1st quarter. Harvest Fund Management Co. Ltd now owns 97,254 shares of the biopharmaceutical company's stock worth $10,892,000 after purchasing an additional 16,365 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.04 during trading hours on Friday, reaching $112.25. 665,766 shares of the stock traded hands, compared to its average volume of 8,396,990. The company has a market capitalization of $139.63 billion, a P/E ratio of 23.61, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 52-week low of $72.43 and a 52-week high of $119.96. The company's 50-day simple moving average is $110.40 and its two-hundred day simple moving average is $106.55.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $978,880.80. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer owned 615,725 shares in the company, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $8,984,175 in the last 90 days. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GILD. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Morgan Stanley increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Finally, Oppenheimer lowered their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $112.36.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.